Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyriproxyfen
- Development stage
- Unknown
- Lead developer
- Sumitomo Chemical
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Pyriproxyfen is a small molecule insect growth regulator (IGR) that acts as a juvenile hormone analogue (JHA). It mimics the natural juvenile hormone in insects, which is essential for regulating development and reproduction. By binding to the juvenile hormone receptor (specifically the Methoprene-tolerant protein), pyriproxyfen disrupts the transition between life stages, preventing larvae from maturing into adults and inhibiting egg hatching. It is characterized by high photostability and low mammalian toxicity. While primarily used in agriculture and veterinary medicine for flea and pest control, it is being investigated by the International Centre of Insect Physiology and Ecology (ICIPE) for the control of tungiasis (sand flea infestation) through environmental application in endemic regions.
- Brand names
- NylarPivotDistanceSumilarvKnackArcherAdmiral
- Other names
- 4-phenoxyphenyl (RS)-2-(2-pyridyloxy)propyl ether4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on pyriproxyfen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyriproxyfen.